Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.

Int J Chron Obstruct Pulmon Dis · 2015 · PMC4293291 · PMID 25609940

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

showed a trendno p-value reported

In this study, glycopyrronium showed a trend towards reduction in the risk of exacerbation both in terms of rate and time to first moderate and severe COPD exacerbations, although this finding did not reach statistical significance.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.